Home » Stocks » SUPN

Supernus Pharmaceuticals, Inc. (SUPN)

Stock Price: $31.13 USD 0.19 (0.61%)
Updated May 18, 2021 12:35 PM EDT - Market open
Market Cap 1.63B
Revenue (ttm) 556.35M
Net Income (ttm) 111.13M
Shares Out 52.93M
EPS (ttm) 2.07
PE Ratio 15.07
Forward PE 20.16
Dividend n/a
Dividend Yield n/a
Trading Day May 18
Last Price $31.13
Previous Close $30.94
Change ($) 0.19
Change (%) 0.61%
Day's Open 30.93
Day's Range 30.81 - 31.50
Day's Volume 116,706
52-Week Range 17.20 - 32.31

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Supernus (SUPN) delivered earnings and revenue surprises of -57.69% and -0.63%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

ROCKVILLE, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of centra...

1 week ago - GlobeNewsWire

ROCKVILLE, Md., May 04, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of centra...

1 week ago - GlobeNewsWire

Supernus (SUPN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago - Zacks Investment Research

ROCKVILLE, Md., April 27, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent...

2 weeks ago - GlobeNewsWire

Supernus (SUPN) gets FDA approval for ADHD treatment, Qelbree, in pediatric patients 6 to 17 years of age.

1 month ago - Zacks Investment Research

The biopharmaceutical company released a regulatory update.

1 month ago - The Motley Fool

They've both taken a beating, but their fortunes may soon change.

Other stocks mentioned: ACAD
1 month ago - The Motley Fool

Qelbree (viloxazine extended-release capsules) represents the first novel non-stimulant treatment for ADHD in a decade

1 month ago - GlobeNewsWire

With solid revenue growth, these stocks have the potential to more than triple over the next few years.

Other stocks mentioned: CORT, CPRX
1 month ago - The Motley Fool

As bond yields retreated to 1.52% after trading as high as 1.62% yesterday, the indices popped. Meanwhile, Q.ai's Artificial Intelligence Systems have crunched the numbers to bring you today's best top ...

Other stocks mentioned: BG, EYE, R, TSE
2 months ago - Forbes

Stocks saw mild gains due to optimism after the $1.9 trillion stimulus bill passed the Senate over the weekend. In the meantime, Q.ai's Artificial Intelligence has crunched the numbers to bring you toda...

Other stocks mentioned: BBY, LEN, LOPE, XPO
2 months ago - Forbes

Their recent struggles may soon give way to rising market interest and more lucrative returns.

Other stocks mentioned: CHRS, IRWD
2 months ago - The Motley Fool

ROCKVILLE, Md., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central ...

2 months ago - GlobeNewsWire

Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 8.06% over the past year to $0.57, whi...

2 months ago - Benzinga

ROCKVILLE, Md., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of centr...

2 months ago - GlobeNewsWire

Supernus Pharmaceuticals saw its IBD SmartSelect Composite Rating rise to 96 Thursday, up from 94 the day before. The post Top-Rated Stocks: Supernus Pharmaceuticals Sees Composite Rating Climb To 96 ap...

2 months ago - Investors Business Daily

ROCKVILLE, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of centr...

2 months ago - GlobeNewsWire

ROCKVILLE, Md., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of centr...

3 months ago - GlobeNewsWire

If you pick securities whose earnings return is more than twice that of the 20-year high-quality market corporate bonds, you could increase your probability to unearth value opportunities, in my opinion...

Other stocks mentioned: BIO, FVE
4 months ago - GuruFocus

ROCKVILLE, Md., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central ...

4 months ago - GlobeNewsWire

It has been eight months since we last looked in on a promising biopharma concern named Supernus Pharmaceuticals. Some significant news has posted since then including some recently disclosed encouragin...

4 months ago - Seeking Alpha

The company announced positive results from a clinical trial.

4 months ago - The Motley Fool

The shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) are up 17.7% at $26.50 at last check, after its experimental drug for attention deficit hyperactivity disorder (ADHD), SPN-812, met its main goal...

4 months ago - Schaeffers Research

Supernus Pharmaceuticals Inc (NASDAQ: SUPN) announced Monday that its SPN-812 — a commercial treatment for patients with Attention Deficit Hyperactivity Disorder (ADHD), exhibited positive topline resul...

4 months ago - Benzinga

Supernus Pharmaceuticals Inc. shares jumped more than 20% in after-hours trading Tuesday after the company revealed positive results from a study of its potential drug for attention deficit hyperactivit...

4 months ago - Market Watch

ROCKVILLE, Md., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central ...

4 months ago - GlobeNewsWire

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q1 2021.

Other stocks mentioned: AMPH, AMRX, BIIB, HZNP, PAHC
5 months ago - Investopedia

Let's see if Supernus Pharmaceuticals (SUPN) stock is a good choice for value-oriented investors right now from multiple angles.

5 months ago - Zacks Investment Research

NEW YORK, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. (“Supernus or the “Company”) (NASDAQ: SUPN). Such investors are...

5 months ago - GlobeNewsWire

LOS ANGELES--(BUSINESS WIRE)---- $SUPN #classaction--The Law Offices of Frank R. Cruz announces an investigation of Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) (NASDAQ: SUPN) on behalf ...

5 months ago - Business Wire

BENSALEM, Pa.--(BUSINESS WIRE)---- $SUPN #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors

5 months ago - Business Wire

ROCKVILLE, Md., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central ...

5 months ago - GlobeNewsWire

LOS ANGELES--(BUSINESS WIRE)---- $SUPN #CLASSACTION--Glancy Prongay & Murray LLP, Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc (SUPN) on Behalf of Investors

5 months ago - Business Wire

ROCKVILLE, Md., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central ...

6 months ago - GlobeNewsWire

NEW YORK, Nov. 11, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. ("Supernus or the "Company") (NASDAQ: SUPN). Such investors are adv...

6 months ago - PRNewsWire

ROCKVILLE, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central ...

6 months ago - GlobeNewsWire

Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Supernus (SUPN) delivered earnings and revenue surprises of 174.07% and 18.11%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

ROCKVILLE, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central ...

6 months ago - GlobeNewsWire

ROCKVILLE, Md., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central ...

6 months ago - GlobeNewsWire

Investors who are looking for high return investments might be interested in the three non-cyclical stocks listed below, as their earnings yields (as calculated via Joel Greenblatt's method) are in the ...

Other stocks mentioned: ENIA, TKC
6 months ago - GuruFocus

Greg Patrick to Retire as Chief Financial Officer Greg Patrick to Retire as Chief Financial Officer

7 months ago - GlobeNewsWire

Supernus is solidly on track for a new record of net sales this year and is still generating huge amounts of free cash flow.

7 months ago - Seeking Alpha

These stocks are just temporarily inconvenienced large caps in the making.

Other stocks mentioned: ADUS, INVA
7 months ago - The Motley Fool

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2020.

Other stocks mentioned: AZN, BIIB, MNTA, NLTX, PRGO, RLMD, SNY ...
8 months ago - Investopedia

ROCKVILLE, Md., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of centr...

8 months ago - GlobeNewsWire

ROCKVILLE, Md., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of centr...

8 months ago - GlobeNewsWire

ROCKVILLE, Md., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of centr...

8 months ago - GlobeNewsWire

Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

About SUPN

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its commercial products include Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The co... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
May 1, 2012
CEO
Jack Khattar
Employees
563
Stock Exchange
NASDAQ
Ticker Symbol
SUPN
Full Company Profile

Financial Performance

In 2020, SUPN's revenue was $520.40 million, an increase of 32.50% compared to the previous year's $392.76 million. Earnings were $126.95 million, an increase of 12.29%.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for SUPN stock is "Buy." The 12-month stock price forecast is 35.00, which is an increase of 12.43% from the latest price.

Price Target
$35.00
(12.43% upside)
Analyst Consensus: Buy